Corona Remedies Ltd on Monday announced the acquisition of Wokadine, a 46-year-old trusted brand, from Dr. Reddy’s Laboratories Ltd. This marks its fifth acquisition and a strategic entry into the ₹648-crore povidone iodine market in India.
The deal, funded through internal accruals and cash, strengthens Corona’s presence in specialty therapies and expands its play in the anti-infective and wound care space, the Ahmedabad-based company stated in an official release. Wokadine, a well-established brand with over four decades of market presence, ranks among the top players in the povidone iodine category in India.
With this acquisition, Corona Remedies aims to leverage its existing sales and distribution network to scale the brand further and deepen its reach across both metro and non-metro markets. The portfolio includes 14 SKUs catering to multiple clinical applications, offering a broader presence across surgical and primary care segments. The acquisition is expected to create synergies with the company’s existing therapeutic portfolio while enhancing its positioning in hospital-driven segments.
This marks Corona Remedies’ fifth acquisition and underscores its focus on building scale through targeted brand buyouts in high-growth therapy areas. Commenting on the development, Tejas Kothari, Vice President – Corporate Strategy & Business Development, stated that the company remains focused on both organic and inorganic opportunities to strengthen its portfolio. He added that the integration of Wokadine is expected to accelerate growth by leveraging Corona’s strong distribution backbone and brand equity among the medical fraternity.